We are live on ! Find out more
HTGM

HTG Molecular Diagnostics

Delisted

HTGM was delisted on the 14th of June, 2023.

47 hedge funds and large institutions have $36.7M invested in HTG Molecular Diagnostics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,400% more call options, than puts

Call options by funds: $30K | Put options by funds: $2K

78% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 9

4.07% more ownership

Funds ownership: 46.69% → 50.76% (+4.1%)

2% more capital inflows, than outflows

Capital inflows: $11.9M | Capital outflows: $11.6M

13% less funds holding

Funds holding: 54 → 47 (-7)

44% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 16

Holders
47
Holders Change
-7
Holders Change %
-12.96%
% of All Funds
1.04%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
16
Reduced
9
Closed
16
Calls
$30​K
Puts
$2​K
Net Calls
+$28​K
Net Calls Change
-⁠$30​K

HTGM Hedge Fund Activity: Q4 2018 in Review

47 of the 4,504 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics (HTGM) for Q4 2018, worth a combined $36.7M — down 45% from $67M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of HTGM and 9 opened new positions — a net loss of 7 holders — while 9 trimmed existing stakes and 16 added.

The largest buyer was Stonepine Capital Management, adding an estimated $7.37M. The largest seller was Private Wealth Partners, exiting entirely with an estimated $5.05M sold.

  • 47 institutional investors held HTG Molecular Diagnostics (HTGM) as of Q4 2018, down from 54 in Q3 2018.
  • Funds reported $36.7M of HTG Molecular Diagnostics stock for Q4 2018, down 45% quarter-over-quarter.
  • 9 funds opened new HTG Molecular Diagnostics positions in Q4 2018 and 16 closed out, a net change of -7 holders.
  • The largest HTG Molecular Diagnostics buyer in Q4 2018 was Stonepine Capital Management, an estimated $7.37M added.
  • The largest HTG Molecular Diagnostics seller in Q4 2018 was Private Wealth Partners, an estimated $5.05M sold.

Based on aggregated 13F filings for Q4 2018.